Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3 program.
- Home |
- Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
- September 24, 2026
Recent Posts
- Tight product supplies lift US summer refinery utilization to highest level since 1998
- Valero wraps St. Charles FCC project, reports record earnings
- EIA: US crude oil inventories down 3.1 million bbl
- Adura gets NSTA consent to develop Jackdaw North Sea gas field
- bp signs MoU with TechnipFMC for subsea production systems earmarked for Paleogene projects
